WHAT IS CLAIMED IS:

1. Use of a pharmaceutical composition in the manufacture of a medicament for treating symptomatic neurogenic orthostatic hypotension (nOH) in a subject having multiple system atrophy (MSA), wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and about 10 mg (free base equivalents) of ampreloxetine or a pharmaceutically acceptable salt thereof and is to be administered daily to the subject for at least about 22 weeks, wherein:

(a) the subject being treated experiences symptoms of neurogenic orthostatic hypotension in the absence of treatment with the pharmaceutical composition as determined using the Orthostatic Hypotension Assessment Scale (OHSA); and

(b) administration of the pharmaceutical composition daily to the subject for at least about 22 weeks results in a measurable reduction in at least one of (i) the subject's OHSA composite score, (ii) Orthostatic Hypotension Questionnaire (OHQ) composite score, (iii) Orthostatic Hypotension Daily Activity Scale (OHDAS) composite score, or (iv) OHDAS item 1 (standing short time).

2. The use of claim 1, wherein the pharmaceutical composition is to be administered to the subject orally.

3. The use of claim 1 or 2, wherein the pharmaceutical composition is to be administered to the subject once per day.

4. The use of any one of claims 1 to 3, wherein the supine plasma norepinephrine level in the subject is less than about 350 pg/mL before treatment with the pharmaceutical composition.

5. The use of any one of claims 1 to 3, wherein the supine plasma norepinephrine level in the subject is greater than about 500 pg/mL after about 8 weeks of treatment with the pharmaceutical composition.

6. The use of any one of claims 1 to 4, wherein the subject has MSA subtype P (MSA-P).

7. The use of any one of claims 1 to 5, wherein the subject has been diagnosed with MSA for at least 1.3 years before the treatment.

8. The use of any one of claims 1 to 7, wherein the subject had onset of nOH 1.6 years or more before the treatment.

9. The use of any one of claims 1 to 8, wherein the subject had an OSHA composite score of 5 or greater before the treatment.

10. The use of any one of claims 2 to 9, wherein the subject had an OSHA item 1 score of 7 or greater before the treatment.

11. The use of any one of claims 1 to 10, wherein the subject has a score ≤4 on Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV before the treatment.

12. The use of any one of claims 1 to 10, wherein the subject has a score of 4 on Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV before the treatment.

13. The use of any one of claims 1 to 12, wherein ampreloxetine is to be administered as a hydrochloride salt.

14. The use of any one of claims 1 to 13, wherein the pharmaceutical composition is to be administered for at least about 12 months.

15. The use of any one of claims 1 to 14, wherein the pharmaceutically acceptable carrier comprises one or more of microcrystalline cellulose, lactose and magnesium stearate.